HRP20211652T1 - Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze - Google Patents
Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze Download PDFInfo
- Publication number
- HRP20211652T1 HRP20211652T1 HRP20211652TT HRP20211652T HRP20211652T1 HR P20211652 T1 HRP20211652 T1 HR P20211652T1 HR P20211652T T HRP20211652T T HR P20211652TT HR P20211652 T HRP20211652 T HR P20211652T HR P20211652 T1 HRP20211652 T1 HR P20211652T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- cancers
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical preparation
- Prior art date
Links
- RLJCWYYOGHGGBV-UHFFFAOYSA-N 1h-pyrimido[5,4-d]pyrimidin-2-one Chemical class C1=NC=C2NC(=O)N=CC2=N1 RLJCWYYOGHGGBV-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 150000001204 N-oxides Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000000349 mediastinal cancer Diseases 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000003695 paranasal sinus Anatomy 0.000 claims 1
- 210000002990 parathyroid gland Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Spoj koji ima formulu (I):
[image]
ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat.
2. Farmaceutski pripravak koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol ili N-oksidni derivat, i najmanje jedan farmaceutski prihvatljiv ekscipijent.
3. Farmaceutski pripravak prema patentnom zahtjevu 2 koji sadrži jedan ili više dodatnih farmaceutski aktivnih agenasa.
4. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u terapiji.
5. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu kao medikament.
6. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u liječenju ili sprječavanju raka.
7. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u skladu sa patentnim zahtjevom 6, naznačen time što je rak odabran iz grupe koja se sastoji od rakova srca, rakova pluća, gastrointestinalnih rakova, rakova genitourinarnog trakta, rakova jetre, rakova kostiju, rakova živčanog sustava, ginekoloških rakova, hematoloških rakova, rakova kože i rakova nadbubrežnih žlijezda, i rakova kao što su tumori nadbubrežnih žlijezda, žučnih puteva, mokraćnog mjehura, krvi, koštanog i vezivnog tkiva, mozga i centralnog živčanog sustava, dojke, grlića maternice, debelog crijeva i rektuma (kolorektalni), endometrija, jednjaka, žučnog mjehura, glave i vrata, Hodkinov limfom, hipofaringealni, bubrega, larinksa, leukemije, jetre, pluća, limfom, medijastinalni tumori, melanom (maligni melanom), mezoteliom, multipli mijelom, nosne šupljine, nazofaringealni, neuroendokrini tumori, ne-Hodkinov limfom, oralni, jednjaka, orofaringealni, jajnika, gušterače, paranazalnih sinusa, paratiroidne žlijezde, penisa, tumori hipofize, prostate, žlijezde slinovnice, sarkom, kože, kičme, želuca, testisa, štitne žlijezde, uretre, maternice, vagine i vulve.
8. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u skladu sa patentnim zahtjevom 6, naznačen time što je rak odabran od raka debelog crijeva i rektuma (kolorektalni), raka glave i vrata, raka pluća, raka jednjaka, raka jajnika i raka gušterače.
9. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u skladu sa patentnim zahtjevom 6, naznačen time što je rak rak pluća.
10. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u skladu sa patentnim zahtjevom 6, naznačen time što je rak rak jajnika.
11. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili N-oksidni derivat, ili farmaceutski pripravak prema patentnom zahtjevu 2 ili 3, za uporabu u skladu sa patentnim zahtjevom 6, naznačen time što je rak rak mozga i centralnog živčanog sustava.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703881.1A GB201703881D0 (en) | 2017-03-10 | 2017-03-10 | Pharmaceutical compounds |
| EP18711666.0A EP3592745B1 (en) | 2017-03-10 | 2018-03-12 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| PCT/GB2018/050620 WO2018162932A1 (en) | 2017-03-10 | 2018-03-12 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211652T1 true HRP20211652T1 (hr) | 2022-02-04 |
Family
ID=58605309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211652TT HRP20211652T1 (hr) | 2017-03-10 | 2018-03-12 | Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11208413B2 (hr) |
| EP (1) | EP3592745B1 (hr) |
| JP (1) | JP7244430B2 (hr) |
| KR (1) | KR102605546B1 (hr) |
| CN (1) | CN110603256B (hr) |
| AU (1) | AU2018231671B2 (hr) |
| BR (1) | BR112019018753A2 (hr) |
| CA (1) | CA3055874A1 (hr) |
| CL (1) | CL2019002557A1 (hr) |
| CY (1) | CY1124613T1 (hr) |
| DK (1) | DK3592745T3 (hr) |
| EA (1) | EA201992137A1 (hr) |
| ES (1) | ES2895365T3 (hr) |
| GB (1) | GB201703881D0 (hr) |
| HR (1) | HRP20211652T1 (hr) |
| HU (1) | HUE056220T2 (hr) |
| IL (1) | IL269063B (hr) |
| LT (1) | LT3592745T (hr) |
| MA (1) | MA47736B1 (hr) |
| MX (1) | MX2019010554A (hr) |
| MY (1) | MY195580A (hr) |
| PH (1) | PH12019502049A1 (hr) |
| PL (1) | PL3592745T3 (hr) |
| PT (1) | PT3592745T (hr) |
| RS (1) | RS62464B1 (hr) |
| SA (1) | SA519410093B1 (hr) |
| SG (1) | SG11201908114UA (hr) |
| SI (1) | SI3592745T1 (hr) |
| UA (1) | UA125093C2 (hr) |
| WO (1) | WO2018162932A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| US11299493B2 (en) | 2017-10-09 | 2022-04-12 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| BR112021019703A2 (pt) | 2019-04-09 | 2021-12-14 | Nuvation Bio Inc | Compostos heterocíclicos e usos dos mesmos |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| EP3952879A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2023083194A1 (zh) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1蛋白激酶降解剂及其用途 |
| WO2023170065A1 (en) * | 2022-03-07 | 2023-09-14 | Debiopharm International S.A. | Methods of treating small cell lung cancer |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| EP2376494A4 (en) | 2008-12-12 | 2012-07-11 | Msd Kk | DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES |
| EP2817308B1 (en) | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2017
- 2017-03-10 GB GBGB1703881.1A patent/GB201703881D0/en not_active Ceased
-
2018
- 2018-03-12 EP EP18711666.0A patent/EP3592745B1/en active Active
- 2018-03-12 US US16/492,292 patent/US11208413B2/en active Active
- 2018-03-12 ES ES18711666T patent/ES2895365T3/es active Active
- 2018-03-12 DK DK18711666.0T patent/DK3592745T3/da active
- 2018-03-12 UA UAA201910268A patent/UA125093C2/uk unknown
- 2018-03-12 CA CA3055874A patent/CA3055874A1/en active Pending
- 2018-03-12 AU AU2018231671A patent/AU2018231671B2/en active Active
- 2018-03-12 CN CN201880016390.8A patent/CN110603256B/zh active Active
- 2018-03-12 PL PL18711666T patent/PL3592745T3/pl unknown
- 2018-03-12 MY MYPI2019005160A patent/MY195580A/en unknown
- 2018-03-12 HU HUE18711666A patent/HUE056220T2/hu unknown
- 2018-03-12 HR HRP20211652TT patent/HRP20211652T1/hr unknown
- 2018-03-12 PT PT187116660T patent/PT3592745T/pt unknown
- 2018-03-12 MA MA47736A patent/MA47736B1/fr unknown
- 2018-03-12 EA EA201992137A patent/EA201992137A1/ru unknown
- 2018-03-12 KR KR1020197029457A patent/KR102605546B1/ko active IP Right Grant
- 2018-03-12 BR BR112019018753A patent/BR112019018753A2/pt unknown
- 2018-03-12 RS RS20211277A patent/RS62464B1/sr unknown
- 2018-03-12 JP JP2019548963A patent/JP7244430B2/ja active Active
- 2018-03-12 LT LTEPPCT/GB2018/050620T patent/LT3592745T/lt unknown
- 2018-03-12 WO PCT/GB2018/050620 patent/WO2018162932A1/en active Application Filing
- 2018-03-12 MX MX2019010554A patent/MX2019010554A/es unknown
- 2018-03-12 SG SG11201908114U patent/SG11201908114UA/en unknown
- 2018-03-12 SI SI201830430T patent/SI3592745T1/sl unknown
-
2019
- 2019-09-02 IL IL269063A patent/IL269063B/en unknown
- 2019-09-06 CL CL2019002557A patent/CL2019002557A1/es unknown
- 2019-09-09 PH PH12019502049A patent/PH12019502049A1/en unknown
- 2019-09-10 SA SA519410093A patent/SA519410093B1/ar unknown
-
2021
- 2021-10-20 CY CY20211100913T patent/CY1124613T1/el unknown
- 2021-12-03 US US17/541,362 patent/US20220194947A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211652T1 (hr) | Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze | |
| JP2015520753A5 (hr) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| JOP20190151A1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| HRP20170306T1 (hr) | Identifikacija izvanstaničnog oblika pten-a koj se može primjenjivati u liječenju tumora | |
| IL257219A (en) | Prodrugs of glutamine analogues | |
| HRP20200180T1 (hr) | Derivati (aza-)izokinolinona | |
| CN103402519B (zh) | 肿瘤治疗剂 | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2018510850A5 (hr) | ||
| EA201992418A1 (ru) | Бициклические соединения и их применение в лечении рака | |
| JP2014526462A5 (hr) | ||
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| JP2015232006A5 (hr) | ||
| RU2014102935A (ru) | Кризотиниб для применения в лечении рака | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| HRP20210228T1 (hr) | Amidi pirola kao inhibitori alfa v integrina | |
| NZ588710A (en) | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | |
| RU2018126793A (ru) | Тетрагидропиранил амино-пирролопиримидинон и способы его применения | |
| RU2013128612A (ru) | Соли и кристаллические формы индуцирующего апоптоз агента | |
| MX2016010127A (es) | Conjugados de anticuerpo-farmaco e inmunotoxinas. | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2015511609A5 (hr) | ||
| RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения |